slides · global inventory
Problem Agitate Solution
Arc collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 26,550
Current window 20,611-20,640
Pages 885
Rows per page 30
Arc
20,611-20,640 of 26,550
20
The chart shows density vs -log10Kd, comparing design vs validation vs measured trastuzumab.Absci | Investor Presentation Deck | 30 slides · Absci
Pitch deck Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
21
The slide highlights the methodology of sampling sequence space and validating predictive models against measured binding affinity.Absci | Investor Presentation Deck | 30 slides · Absci
Pitch deck Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
22
The chart compares High vs Low Fidelity models with and without pretraining across different training data sizes.Absci | Investor Presentation Deck | 30 slides · Absci
Pitch deck Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
23
The slide shows scatter plots for quadruple and quintuple mutants and a summary bar chart for performance metrics.Absci | Investor Presentation Deck | 30 slides · Absci
Pitch deck Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
24
The slide uses a combination of diagrams and a summary box to explain the methodology of using AI to predict antibody naturalness.Absci | Investor Presentation Deck | 30 slides · Absci
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
25
The slide uses box plots and bar charts to show statistical correlation between naturalness and clinical/developability outcomes.Absci | Investor Presentation Deck | 30 slides · Absci
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
26
The slide uses box plots and density plots to demonstrate that higher naturalness correlates with better expression and lower mutational burden.Absci | Investor Presentation Deck | 30 slides · Absci
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
27
The charts show the progression of antibody variants over generations, highlighting the improvement in ACE score and naturalness metrics.Absci | Investor Presentation Deck | 30 slides · Absci
Pitch deck Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
28
The slide uses a process diagram to illustrate the 'in silico' lead optimization workflow.Absci | Investor Presentation Deck | 30 slides · Absci
Pitch deck Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
29
The slide uses a process flow diagram to show the integration of AI in drug development.Absci | Investor Presentation Deck | 30 slides · Absci
Pitch deck Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
07
The slide uses a hierarchical diagram to map the clinical manifestations of the disease.Aeglea BioTherapeutics | Investor Day Presentation Deck | 28 slides · Aeglea BioTherapeutics
Conference presentation Investor relations Beat · Problem (Identify pain)1 hit
08
The diagram illustrates the metabolic pathway and the specific block at the Cystathionine beta-synthase step.Aeglea BioTherapeutics | Investor Day Presentation Deck | 28 slides · Aeglea BioTherapeutics
Conference presentation Investor relations Beat · Problem (Identify pain)1 hit
09
The table contrasts clinical outcomes (Hcy levels, lens dislocation, IQ, thrombosis, mortality) between two patient cohorts.Aeglea BioTherapeutics | Investor Day Presentation Deck | 28 slides · Aeglea BioTherapeutics
Conference presentation Investor relations Beat · Problem (Identify pain)1 hit
10
Includes a citation of the specific clinical guidelines paper.Aeglea BioTherapeutics | Investor Day Presentation Deck | 28 slides · Aeglea BioTherapeutics
Conference presentation Investor relations Beat · Problem (Identify pain)1 hit
11
Includes historical context of diagnostic methods (pre-NBS era).Aeglea BioTherapeutics | Investor Day Presentation Deck | 28 slides · Aeglea BioTherapeutics
Conference presentation Investor relations Beat · Agitate (Make it worse)Loop · Cost Of Inaction1 hit
12
The slide uses a table to show symptom overlap (+) and absence (-) between two conditions, accompanied by a visual comparison of patients.Aeglea BioTherapeutics | Investor Day Presentation Deck | 28 slides · Aeglea BioTherapeutics
Conference presentation Investor relations Beat · Agitate (Make it worse)Loop · Cost Of Inaction1 hit
13
The slide highlights the clinical consequences of missing HCU in newborn screening (NBS).Aeglea BioTherapeutics | Investor Day Presentation Deck | 28 slides · Aeglea BioTherapeutics
Conference presentation Investor relations Beat · Agitate (Make it worse)Loop · Cost Of Inaction1 hit
14
The slide displays various medical nutrition products used for HCU management.Aeglea BioTherapeutics | Investor Day Presentation Deck | 28 slides · Aeglea BioTherapeutics
Conference presentation Investor relations Beat · Agitate (Make it worse)Loop · Cost Of Inaction1 hit
20
Aeglea BioTherapeutics | Investor Day Presentation Deck | 28 slidesAeglea BioTherapeutics | Investor Day Presentation Deck | 28 slides · Aeglea BioTherapeutics
Conference presentation Investor relations Beat · Solution (Provide relief)Loop · Jobs To Be Done1 hit
21
The slide uses a pie chart to show patient segmentation by B6 responsiveness and a timeline/number-line to show age of diagnosis, followed by key metrics on complication rates.Aeglea BioTherapeutics | Investor Day Presentation Deck | 28 slides · Aeglea BioTherapeutics
Conference presentation Investor relations Beat · Solution (Provide relief)Loop · Jobs To Be Done1 hit
22
Aeglea BioTherapeutics | Investor Day Presentation Deck | 28 slidesAeglea BioTherapeutics | Investor Day Presentation Deck | 28 slides · Aeglea BioTherapeutics
Conference presentation Investor relations Beat · Solution (Provide relief)Loop · Jobs To Be Done1 hit
23
The slide uses a process flow diagram to show the metabolic block (CBS deficiency) and the therapeutic intervention point.Aeglea BioTherapeutics | Investor Day Presentation Deck | 28 slides · Aeglea BioTherapeutics
Conference presentation Investor relations Beat · Solution (Provide relief)Loop · Jobs To Be Done1 hit
24
The slide uses a biological process diagram to contrast normal intracellular metabolism with the therapeutic effect of the drug in the plasma.Aeglea BioTherapeutics | Investor Day Presentation Deck | 28 slides · Aeglea BioTherapeutics
Conference presentation Investor relations Beat · Solution (Provide relief)Loop · Jobs To Be Done1 hit
07
The slide outlines a standard randomized controlled trial (RCT) design for a pharmaceutical study.Albireo Pharma | Results Presentation Deck | 18 slides · Albireo Pharma
Conference presentation Investor relations Beat · Agitate1 hit
08
The slide includes a footer note regarding patient completion rates.Albireo Pharma | Results Presentation Deck | 18 slides · Albireo Pharma
Conference presentation Investor relations Beat · Agitate1 hit
09
Clinical trial data showing efficacy of Odevixibat (Bylvay) vs Placebo.Albireo Pharma | Results Presentation Deck | 18 slides · Albireo Pharma
Conference presentation Investor relations Beat · SolutionLoop · Before After1 hit
10
The chart displays LS Mean (95% CI) with p-value significance markers.Albireo Pharma | Results Presentation Deck | 18 slides · Albireo Pharma
Conference presentation Investor relations Beat · SolutionLoop · Before After1 hit
11
The chart shows statistically significant improvements (p<=0.01) for the treatment group across all time points after baseline.Albireo Pharma | Results Presentation Deck | 18 slides · Albireo Pharma
Conference presentation Investor relations Beat · SolutionLoop · Before After1 hit
12
The p-values indicate statistical significance for the listed improvements.Albireo Pharma | Results Presentation Deck | 18 slides · Albireo Pharma
Conference presentation Investor relations Beat · SolutionLoop · Before After1 hit
13
The slide highlights safety data for Odevixibat (Bylvay) over 24 weeks.Albireo Pharma | Results Presentation Deck | 18 slides · Albireo Pharma
Conference presentation Investor relations Beat · Solution1 hit